Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 233Head and Neck Neoplasms 150Squamous Cell Carcinoma of Head and Neck 136Stomach Neoplasms 117Lung Neoplasms 109Esophageal Neoplasms 90Uterine Cervical Neoplasms 72Neoplasms 67Urinary Bladder Neoplasms 56Breast Neoplasms 48Ovarian Neoplasms 46Esophageal Squamous Cell Carcinoma 45Pancreatic Neoplasms 44Small Cell Lung Carcinoma 42Neoplasm Metastasis 40Adenocarcinoma Of Esophagus 38Carcinoma, Squamous Cell 33Carcinoma, Ovarian Epithelial 32Mesothelioma, Malignant 30Lymphoma 28Parkinson Disease 4, Autosomal Dominant Lewy Body 27Adenocarcinoma of Lung 25Sarcoma 24Cholangiocarcinoma 24Nasopharyngeal Carcinoma 22Carcinoma 22Unspecified Adult Solid Tumor, Protocol Specific 21Neuroblastoma 21Gallbladder Neoplasms 21Central Nervous System Neoplasms 21

Interventions

berzosertib 1Platinum 1Gemcitabine 1Cisplatin 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Metastatic Bladder Urothelial Carcinoma × Cisplatin × Clear all
NCT02567409 2025-03-03

Cisplatin and Gemcitabine Hydrochloride With or Without Berzosertib in Treating Patients With Metastatic Urothelial Cancer

National Cancer Institute (NCI)

Phase 2 Completed
87 enrolled 13 charts
Genitourinary

Metastatic Bladder Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡